Сравнение

Eloralintide vs. Petrelintide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Eloralintide	Petrelintide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Eloralintide and Petrelintide?: Eloralintide is classified as "Метаболизм", while Petrelintide is classified as "Метаболизм". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Petrelintide?: The highest available evidence level is "РКИ на людях" for Eloralintide and "РКИ на людях" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Petrelintide in Germany and the United States?: Германия: Eloralintide — Не одобрено, Petrelintide — Не одобрено. США: Eloralintide — Не одобрено, Petrelintide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Petrelintide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Eloralintide and Petrelintide?

Eloralintide is classified as "Метаболизм", while Petrelintide is classified as "Метаболизм". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Petrelintide?

The highest available evidence level is "РКИ на людях" for Eloralintide and "РКИ на людях" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Petrelintide in Germany and the United States?

Германия: Eloralintide — Не одобрено, Petrelintide — Не одобрено. США: Eloralintide — Не одобрено, Petrelintide — Не одобрено. These are factual summaries with source and review date on the individual pages.